This Tuesday, January 24, they will begin to be distributed in the Argentina the doses of bivalent vaccines either bivariate against him COVID-19. The Ministry of Health of the Nation it will send them to the 24 jurisdictions and they will be applied as part of the immunization strategic plan, which already included vaccines developed based on different platforms.
Bivalent vaccines have not yet arrived in Argentina, but they are already applied in other countries in the region
These are the second generation developments adapted to the Ómicron variant. As Infobae announced, the negotiations between the government and the Moderna pharmaceutical company are advanced. This afternoon Minister Carla Vizzotti will offer a press conference in which she will announce the arrival of these new inoculants in the country
The health authorities received a first delivery of 901,440 doses of Pfizer/BioNTech bivariate vaccines. A second installment includes 1,100,160 doses bivariate vaccine from the same manufacturers. From tomorrow the distribution of 900,000 doses will begin of those inoculants to the whole country.
Regarding the start of the application, sources from the national Health portfolio said it will be from next weeks according to the strategic plans of each of the jurisdictions.
The Government announced that the bivalent vaccines against COVID-19 will arrive: how will the distribution be throughout the country
It has just been announced by the Minister of Health, Carla Vizzotti. These are the second generation developments adapted to the new Ómicron variants. Pfizer will be the first to arrive between today and tomorrow; and then, from February 6, it will be the turn of Moderna
In the case of the Buenos aires city the application will begin within two days. “Tomorrow they will deliver the doses of bivalent vaccines. On Wednesday they begin to be applied in the city of Buenos Aires, ”he told Infobae Gabriel Battistella, Undersecretary of Primary, Ambulatory and Community Care of the Buenos Aires Ministry of Health.
When consulting sources from the health portfolio of the province of Buenos Aires, They pointed out that they still do not have the start date of the application, since they will first await the arrival of the doses.
Everything you need to know about the arrival of bivalent vaccines against COVID in Argentina
Next week the doses of bivalent or bivariate vaccines will be distributed to the 24 jurisdictions of Argentina. From what ages they will be received, how they differ from other doses, and what happened in other countries when applying them
In other districts, such as the case of jumpFor example, the provincial Ministry of Health reported that this week it will receive a batch of more than 28,000 doses of bivalent COVID-19 vaccines, made by the Pfizer laboratory. These first doses will be distributed in all operational areas, as a response strategy to the pandemic that began in March 2020, he said.
A similar statement was made by the authorities of Mendoza, noting that they are waiting for the Nation to meet the established deadlines to make the official announcement of the start of the application.
For his part, in Santa Fe, the provincial Health Minister, Sonia Martorano, confirmed that this Tuesday the distribution will begin throughout the country and that more than 79,000 doses will arrive in the province, but warned that it is not yet defined what the application will be like. She explained that due to the cold requirement of the bivalents, the distribution will not be “so fast.” However, she assured that it will begin this week.
In the case of chaco “The first 23,000 doses that the Nation sends to the province will arrive during the next week,” Dr. María Laura Lescano, head of the Department of Immunizations of the Ministry of Health of the Province of Chaco, had said on Friday. Immediately the vaccines will be distributed throughout the province.
On the other hand, from February 6th bivalent vaccines will be received next from the biotechnology company modernaccording to the doctor Vizzotti.
Doses of “bivalent” or “bivariate” vaccines have components against the parent virus that causes COVID-19, and against the variant lineages Omicron BA.4 and BA.5. Still is not defined the exact date on which each jurisdiction will begin to apply them.
According to the Minister of Health of the Nation, Carla Vizzottithe bivalent vaccines developed by the company will be applied Pfizer/BioNTech as the modern.
The bivalents are authorized for different ages. In the case of laboratory bivariate doses Pfizer/BioNtech are authorized for use in the general population from the 12 years and older. In the case of laboratory bivariate vaccines modern are authorized for use in the general population from the 6 years onwards.
To obtain authorization for their use, clinical trials have been carried out that evaluated bivalent vaccines. These trials demonstrated that they are safe and effective in providing protection against hospitalizations, complications, and deaths against all circulating variants, as explained by the Health portfolio.
Since December 2020, Argentina has been applying doses monovalent: they contained protection against the ancient strain of the coronavirus that was detected in China in 2020. Those doses also provide protection to reduce the risk of complications and death if a person becomes infected with the coronavirus. In the case of bivalents, specific protection against Omicron BA.4 and BA.5 is added.
Over the next few weeks, will coexist the application of monovalent doses, which remain in stock in the provinces, and bivalent doses. “Those who were vaccinated yesterday with the monovalent vaccine, know that they are protected and that it is very important not to have wasted time receiving that dose. The vaccine that works best is the one that is applied as soon as possible and without losing opportunities,” Vizzotti clarified during a press conference last week.
The recommendation is that people who received their last dose of the COVID vaccine more than four months ago should go for a booster. It doesn’t matter if it’s the first, the second, the third, or even the second dose to complete the primary regimen. It is very important to have vaccination coverage because there is still community transmission of the coronavirus in the country.
From the Health portfolio they emphasized that “all vaccines, whether monovariate or bivariate, are effective in avoiding hospitalizations and deaths. Therefore, they will be co-administered and The one that is available at the time will be given at each vaccination.”
The Pfizer/BioNTech and Moderna bivalent doses are vaccines of messenger RNA. And the monovalent doses from these laboratories have already been applied in Argentina along with vaccines made on the basis of other types of platforms.
For people who have had allergic reactions to doses of messenger RNA vaccines, the Health portfolio plans to apply Sputnik Component I vaccines. Confirmation of the arrival of 500,000 doses of Sputnik Component 1 is expected, according to Vizzotti.
In the region there are already several countries that have begun to offer their population bivalent vaccines. In Chili, As of January 16, it is available to all people over 50 years of age and groups such as teachers and people with immunocompromised conditions.
In Brazil They apply from December to people over 14 years of age. The bivalents are also applied in Peru Y Panama.
A few days ago, the results of a scientific study in Israel. There, the booster was applied with bivalent or bivariate doses from Pfizer/BioNTech. That work revealed that doses drastically reduced hospitalizations among elderly patients. It is one of the first tests of the efficacy of bivalents in the real world.
The study was conducted by researchers from Clalit, Ben-Gurion University of the Negev, and Sapir College, and has not yet been peer-reviewed. The study was conducted from late September to mid-December and looked at 622,701 people over the age of 65 who were eligible for the bivalent booster. Of these, 85,314, that is, 14%, had received it.
An 81% reduction in hospitalizations was found among people 65 and older who had received the booster versus those who had previously received at least two COVID vaccines, but not the bivalent vaccine, the agency reported. Reuters.
Keep reading:
